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Abstract
Background: The immunosuppressive drug rapamycin (RAPA) promotes the expansion of CD4
+ CD25
highFoxp3
+ regulatory
T cells via mechanisms that remain unknown. Here, we studied expansion, IL-2R-c chain signaling, survival pathways and
resistance to apoptosis in human Treg responding to RAPA.
Methodology/Principal Findings: CD4
+CD25
+ and CD4
+CD25
neg T cells were isolated from PBMC of normal controls (n=21)
using AutoMACS. These T cell subsets were cultured in the presence of anti-CD3/CD28 antibodies and 1000 IU/mL IL-2 for 3
to 6 weeks. RAPA (1–100 nM) was added to half of the cultures. After harvest, the cell phenotype, signaling via the PI3K/
mTOR and STAT pathways, expression of survival proteins and Annexin V binding were determined and compared to values
obtained with freshly-separated CD4
+CD25
high and CD4
+CD25
neg T cells. Suppressor function was tested in co-cultures with
autologous CFSE-labeled CD4
+CD25
neg or CD8
+CD25
neg T-cell responders. The frequency and suppressor activity of Treg
were increased after culture of CD4
+CD25
+ T cells in the presence of 1–100 nM RAPA (p,0.001). RAPA-expanded Treg were
largely CD4
+CD25
highFoxp3
+ cells and were resistant to apoptosis, while CD4
+CD25
neg T cells were sensitive. Only Treg
upregulated anti-apoptotic and down-regulated pro-apoptotic proteins. Treg expressed higher levels of the PTEN protein
than CD4
+CD25
neg cells. Activated Treg6RAPA preferentially phosphorylated STAT5 and STAT3 and did not utilize the PI3K/
mTOR pathway.
Conclusions/Significance: RAPA favors Treg expansion and survival by differentially regulating signaling, proliferation and
sensitivity to apoptosis of human effector T cells and Treg after TCR/IL-2 activation.
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Introduction
Naturally occurring CD4
+CD25
highFoxp3
+ regulatory T cells
(nTreg) are essential for maintaining tolerance to self and
regulating immune responses to foreign antigens. Thus, Treg
have been implicated in the pathogenesis of autoimmune diseases,
transplant rejection and infectious diseases [1,2]. However, Treg
can also sabotage antigen-specific immune responses against
tumors as well as microbes and have been proposed as a potential
mechanism of immune suppression in patients with cancer or
chronic HIV-1 infection [3–6].
Recent clinical studies suggest that in patients with autoimmune
or allergic diseases, thymus-derived nTreg are reduced in numbers
[7] and/or have reduced suppressive functions [8–10]. Therefore,
their replacement with CD4
+CD25
+ Treg cells obtained from
normal donors or in vitro expanded autologous functional
CD4
+CD25
+ Treg represents a new paradigm for immunotherapy
of autoimmune diseases. Recent studies in mice have shown that
donor-type CD4
+CD25
+ Treg cells do not induce GVHD after
major histocompatibility complex (MHC)-mismatched bone
marrow transplantation but instead suppress GVHD induced by
non-regulatory donor T cells [11,12]. Importantly, a co-transfer of
CD4
+CD25
+ Treg cells neither interfered with stem cell
engraftment [11,13] nor abrogated the beneficial anti-tumor
activity of donor T-cell infusions [13,14]. These murine studies are
encouraging and provide a solid rationale for investigations of in
vitro expansion strategies and adoptive transfer of human Treg cells
for therapy of T-cell mediated autoimmune diseases or transplant
rejection.
Discrimination of Treg from CD4
+CD25
+ effector non-Treg
(conventional T cells or Tconv) and selective expansion of Treg on
a clinical scale are limiting steps in the development of successful
Treg-based immunotherapy. To date, no specific markers for
human Treg have been identified and validated. Foxp3, a
transcription factor considered by many as the Treg marker,
appears to be also transiently expressed in activated Tconv [15].
We have depended on the isolation of CD4
+CD25
high T-cell
subset in our studies of human nTreg [16]. In contrast to murine
cells, human CD25
high cells are not a clearly-defined, discrete
population, because there exists a large and overlapping
population of CD25
low/interm T cells. Thus, co-purification of
these T cells with CD4
+CD25
high Treg might be responsible for
weak suppressor activity observed in studies of human
CD4
+CD25
+ cells isolated from peripheral blood of normal
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+/CD127
+
cells yields a population of Foxp3
+ Treg which is free of
contaminating CD25
+ effector cells (18). Because CD4
+CD25
high
Treg represent a minor subset (,2%) of the peripheral CD4
+ T
cells in humans [16,17], their in vitro expansion from peripheral
blood for clinical use represents a challenge. To date, human Treg
used in therapy have been obtained from the cord blood [19–21].
Approaches proposed for the elimination of non-Treg cells
overgrowing in cultures of incompletely purified Treg include the
use of the immunosuppressive drug rapamycin (sirolimus, RAPA).
We and Battaglia et al have shown that RAPA selectively
promotes expansion of human CD4
+CD25
highFoxp3
+ T cells
endowed with potent suppressor function in normal donors,
patients with cancer or those with diabetes [16,22,23]. Though
RAPA has been reported to induce Treg-dependent immunosup-
pression in vitro and in vivo [24–27], the exact mechanism of its
action on Treg cells remains largely unknown. We have recently
reported that one of the mechanisms through which RAPA can
enrich for CD4
+CD25
high Treg may be its ability to selectively
induce apoptosis in TCR-activated CD4
+CD25
+ Tconv [16]. In
contrast, activated nTreg which are constitutively CD25
highFox-
p3
high remain resistant to RAPA-mediated apoptosis [16]. These
preliminary results suggest that although human Treg subsets may
express many of the same surface markers or receptors and
produce the same cytokines as conventional CD4
+CD25
2 or
CD4
+CD25
low T cells, proliferation of these T cell subsets in
response to TCR-mediated signals and IL-2 might be differentially
regulated. This divergent regulation via the distinct molecular
pathways could be a key mechanism for maintaining the
homeostatic balance between Treg and Tconv. Further, it could
be exploited for selective in vitro or in vivo expansion of antigen-
specific Treg or T effector cells for therapy of patients with T-cell
mediated diseases.
In this manuscript, we first define optimal conditions for ex vivo
expansion of human Treg in the presence of RAPA and then
demonstrate differential effects of RAPA on Tconv and Treg with
respecttotheBcl-2familyproteinexpression,utilizationoftheSTAT
vs. PI3K/mTOR pathways and the PTEN protein expression.
Results
Responses of Treg (CD4
+CD25
+Foxp3
+) and conventional
(CD4
+CD25
neg) T cells to RAPA in the presence of CD3/
CD28 Ab crosslinking and IL-2
Our initial experiments indicated that RAPA can selectively
promotes expansion of CD4
+CD25
highFoxp3
+ human Treg isolated
from the peripheral circulation of normal donors and activated with
anti-CD3/CD28 Ab+IL-2 [16]. The CD4
+CD25
high T cell subset
used in our experiments was previously shown to consist largely of
Foxp3
+ cells [3,5,16]. Cultured CD4
+CD25
+ cells down-regulated
surfaceexpression ofCD25 inthe absenceof RAPA(R0) (Figure 1A,
left panel). In contrast, the parallel RAPA-containing cultures (+R),
wereenrichedinCD4
+CD25
highTce ll s(Figure1A,right panel).Inthe
+R cultures, CD4
+CD25
+ and CD4
+CD25
high Tc e l l sw e r et h e
expandingcellpopulations.Incontrast,R0cultureslargelycontained
proliferatingCD4
+CD25
negTce ll s(Figure1Bleftpanel).Theseresults
suggested that RAPA inhibited expansion of CD4
+CD25
neg cells
while promoting proliferation of CD4
+CD25
+ Tc e l l s .
Apoptosis of CD4
+CD25
neg T cells in the presence of
RAPA
To analyze whether RAPA inhibits T responder cell prolifer-
ation by selectively inducing apoptosis of CD4
+CD25
neg T cells,
we examined ANX V binding to CD4
+CD25
+ and CD4
+CD25
neg
T cells before and after their culture in the presence of RAPA for
3–6 weeks. Fresh MACS-separated CD4
+CD25
neg cells failed to
bind ANX V, while 45% of autologous CD4
+CD25
+ T cells were
ANX V
+ (Figure 1B, right panels). This result suggests that these
CD4
+CD25
+ T cells were undergoing activation induced cell
death (AICD). In contrast, ANX V binding to CD4
+CD25
neg cells
cultured in the presence of RAPA (+R) for 3 weeks was very high
(90610%), while significantly lower ANX V binding to
CD4
+CD25
neg cells (p,0.0001) was evident in proliferating R0
cultures (Figure 1C). As also shown in Figure 1D for a
representative culture, significantly higher percentages of ANX
V
+ CD4
+CD25
neg T cells were observed in 3 week +R cultures
than of CD4
+CD25
high T cells (95% vs. 15%). Analogous data
were obtained when these cell subsets were cultured+R for 6 weeks
(data not shown). ANX V binding to CD4
+CD25
+ and
CD4
+CD25
neg T cell subsets was similar when these cells were
cultured without RAPA (23614% vs. 20615%; p,0.44; data not
shown).
In addition to ANX V binding, caspase-3 cleavage into its active
fragments was evaluated by Western blots in CD4
+CD25
high and
CD4
+CD25
neg cell subsets +RAPA (Figure 1E). Caspase activity
was observed only in CD4
+CD25
neg cells +RAPA.
These results suggest that apoptosis-sensitive CD4
+CD25
high T
cells become resistant to apoptosis following TCR-mediated+IL-2
activation and subsequent culture in the presence of RAPA. In
contrast, CD4
+CD25
neg T cells become highly sensitive to
apoptosis upon TCR and IL-2-mediated activation in the presence
of RAPA and die.
Proliferation kinetics of Treg and conventional T
cells+RAPA
Next, the proliferation kinetics of autologous CD4
+CD25
+ and
CD4
+CD25
neg T cell subsets6RAPA were monitored by deter-
mining absolute cell numbers weekly during a 3-week expansion
period (Figure 2A, B). The frequency of CD4
+CD25
high T cells in
these cultures was also determined by flow cytometry.
CD4
+CD25
neg T cells proliferated readily in the absence of
RAPA, reaching a substantial fold expansion by week 3
(Figure 2A). CD4
+CD25
neg cells did not proliferate in the presence
of RAPA (Figure 2B). In contrast, both CD4
+CD25
+ and
CD4
+CD25
high T cells showed high expansion in the presence
of RAPA but did not proliferate in its absence (Figure 2A). As
CD4
+CD25
+ T cell subset consists largely of CD4
+CD25
high Treg
(see Figure 2D), the expansion rate of both these subsets is
comparable in the presence of RAPA. Expansion of CD4
+CD25
+
T cells in +R cultures was delayed. This latency period might
reflect the paucity of factors necessary for their proliferation,
despite the presence of feeder cells. However, by week 3, sustained
proliferation of CD4
+CD25
+ and CD4
+CD25
high, but not
CD4
+CD25
neg T cells, occurred, leading to significant expansion
of the CD25
+ subsets (Figure 2B). These findings together with the
observation that RAPA induces apoptosis of nearly all activated
CD4
+CD25
neg T cells suggest that RAPA selectively promotes
expansion of Treg present in PBMC by inducing cell death of
‘‘contaminating’’ CD4
+CD25
neg Tconv.
To determine the optimal concentration of RAPA for expansion
of single cell-sorted CD4
+CD25
high Treg, we set up cultures
containing RAPA at concentrations ranging from 1 to 100 nM.
Figure 2C shows that CD4
+CD25
high T cells obtained from the
blood of six different NC proliferated best at the concentration of
1 nM of RAPA relative to Treg in cultures with higher RAPA
concentrations. Figure S1 shows representative flow cytometry
results for fresh and RAPA-expanded Treg. When the percentages
of CD4
+CD25
high cells were measured within the CD3
+CD4
+
RAPA Favors Expansion of Treg
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+CD25
high T cells expanding6RAPA. A. Gating strategy used to designate
CD25
high and CD25
inter/low T cells within the CD3
+CD4
+ T cell population. Note that after 6 weeks of culture+RAPA, nearly all cells are CD25
high. B. Left
panel, percentages of expanded CD4
+CD25
neg or CD4
+CD25
+ T cells6RAPA after 3 weeks in culture. Data are means6SD cells in 10 cultures initiated
with MACS-purified CD4
+ T-cell subsets. Right panels, ANX V binding to fresh, uncultured MACS-isolated CD4
+CD25
2 and CD4
+CD25
high T cells. A
representative dot blot is shown. C. ANX V binding to CD4
+CD25
2 T cells in 3 week cultures6RAPA. The data are mean percentages6SD of ANX V
+ cells
in 10 cultures. Note that only few CD4
+CD25
neg cells expanding in cultures with no RAPA bind ANX V, while all CD4
+CD25
neg cells present in +RAPA
cultures bind ANX V. D. ANX V binding to CD4
+CD25
neg and CD4
+CD25
high T cells after 3 weeks of culture+1 nM RAPA. A representative dot blot is
shown. E. Western blots of CD4
+CD25
high and CD4
+CD25
neg T cells6RAPA showing caspase-3 activation only in the CD4
+CD25
neg T-cell subset +RAPA.
doi:10.1371/journal.pone.0005994.g001
RAPA Favors Expansion of Treg
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5994Figure 2. Expansion and suppressor activity of CD25
+ T cells cultured in presence of rapamycin. A. Expansion rates of in vitro-expanded
MACS purified human CD4
+CD25
neg, CD4
+CD25
+ and sorted CD4
+CD25
high T cells cultured with irradiated feeder cells, anti-CD3/CD28 Ab-coated
beads and 1,000 IU/mL of IL-2 in the absence of RAPA. Cell counts were performed at weekly intervals throughout culture period. The expansion rate
is the ratio of absolute cell counts after culture vs. counts of the purified (by AutoMACS or sorting) cells before culture. The data are means6SD of
experiments performed with cells of 10 NC. B. Results of the same experiments as in A but performed+1 nM RAPA. C. Expansion after culture for 3
weeks of CD4
+CD25
+ and CD4
+CD25
neg T cells+RAPA used at various concentrations. The data are mean fold expansion6SD from 6 experiments with
cells of different NC. Note the highest fold expansion of CD4
+CD25
high T cells in the presence of 1 nM RAPA (p,0.001). Differences in expansion
between CD4
+CD25
high and CD4
+CD25
neg T cells were also significant at p,0.0001. D. Enrichment of the cultures in CD4
+CD25
high T cells at different
concentrations of RAPA. The gating strategy was to include all CD4
+ T cells in the gate, then to re-gate on CD4
+CD25
high Treg. A representative dot
blot of 5 experiments with cells of different NC is shown.
doi:10.1371/journal.pone.0005994.g002
RAPA Favors Expansion of Treg
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incubation, the highest Treg purity (99%) was obtained in cultures
containing 100 nM of RAPA (Figure 2D). 1 nM RAPA cultures
contained a mean of 76%64 (SD) of CD4
+CD25
high Treg
(Table 1).
Phenotypic characteristics of Treg expanded by RAPA
The phenotype of CD4
+CD25
+ T cells expanded in +R cultures
was significantly different from that of T cells outgrown in R0
cultures (data not shown). The latter were CD4
+CD25
neg and did
not express Foxp3, CTLA-4 or GITR. On the other hand, the
CD4
+CD25
high T cells expanded in +R cultures had the memory
phenotype (CD45RO
+(RA
2)) and expressed the characteristic
Treg markers, including Foxp3, CD62L, CTLA4 and GITR
(Figure 3). These cells were strongly positive for Fas and FasL, and
showed expression of granzymes and TGF-b. Their phenotype
was compared to that of freshly harvested, FACS-sorted
CD4
+CD25
high cells, and the gating used in these experiments is
illustrated in Figure 3, with representative dot plots shown in
Figure S1. Several differences were identified between fresh and
RAPA-expanded Treg (Figure 3). A higher proportion of +R cells
than fresh CD4
+CD25
high Treg expressed TGFb1 and the
chemokine receptors CCR4 and CCR7. Nearly all fresh
CD4
+CD25
high T cells were Foxp3
+, and 100% of the cells in
all +R cultures remained Foxp3
+. No differences in this
phenotypic profile occurred in cells cultured for 3 or 6 weeks
(data not shown). There were no significant differences in the Treg
phenotypic profile in +R cultures established at RAPA concen-
trations ranging from 1 to 100 nM of the drug (data not shown).
Overall, T cells expanded +RAPA had the phenotype that
resembled that of Treg present in the peripheral circulation of NC,
as previously reported by us [16].
Suppressor functions of Treg expanded by RAPA
To evaluate suppressive activity of CD4
+CD25
+ T cells
cultured6RAPA for 3 or 6 weeks, CFSE co-culture assays were
performed. Suppressor (S) T cells (Treg) derived from the R0 or
+R cultures were co-incubated with CFSE-labeled fresh autolo-
gous CD4
+CD25
neg or CD8
+CD25
neg responder T cells (ratio
1S:1RC) stimulated with OKT3 and anti-CD28 Abs in the
presence of 150 IU/mL of IL-2. Nearly complete suppression of
RC proliferation was mediated by CD4
+CD25
+ Treg cells derived
from 3 week cultures +RAPA (Figure 4A). Significantly weaker
suppression (p,0.001) was mediated by Treg cells originating
from R0 cultures (Figure 4B and Table 2). The mean %
suppression obtained in CFSE-based suppression assays for all
the R0 and +R cultures is shown in Figure 4B, while suppression
mediated by CD4
+CD25
+ Treg cells of six NC cultured in the
presence of various concentrations of RAPA is shown in Table 2.
Suppression of RC proliferation was nearly complete with Treg
cells cultured with 100 nM RAPA. Treg cells cultured in 1 nM
RAPA also mediated high levels of suppression, as shown in
Figure 4C and Table 3).
Our results showed that CD4
+CD25
neg Tconv expanded in the
absence of RAPA (R0) contained few functional suppressor Treg.
When CD4
+CD25
neg T cells were co-cultured with autologous RC
as controls in the presence of RAPA, they neither proliferated nor
mediated suppression in CFSE assays. Thus, RAPA did not induce
Treg in the CD4
+CD25
neg T cell subset (data not shown).
Expression of pro- and anti-apoptotic proteins in fresh
and cultured T-cell subsets
Our results indicated that the CD4
+CD25
high Treg generated in
+R cultures mediated potent suppression and were resistant to
spontaneous and activation-induced apoptosis. Apoptosis-sensitive
CD4
+CD25
neg T cells were eliminated in these cultures. To
determine whether survival of TCR-activated Treg in the presence
of RAPA was dependent on the BcL-2 family members, expression
of Bcl-2, Bcl-xL and Bax proteins in T cells was analyzed by flow
cytometry in the parallel +R and R0 cultures.
Expression levels (measured as MFI) of pro-apoptotic Bax and
anti-apoptotic Bcl-xL or Bcl-2 were equal in the apoptosis-resistant
fresh CD4
+CD25
neg T-cells (Figure 5). However, in the apoptosis-
sensitive fresh CD4
+CD25
high T cells, expression levels of Bcl-2
and Bcl-xL were significantly lower than those of Bax, with the
Bcl-2/Bax and Bcl-xL/Bax ratios of 1/6.5 to 1/7.3, respectively
(Figure 5). After culture in the presence of RAPA for 3 weeks,
CD4
+CD25
neg cells were strongly positive for Bax but lost Bcl-2
expression, with the Bcl-2/Bax and Bcl-xL/Bax ratios of 1/96 and
1/68, respectively. In contrast, in the CD4
+CD25
high T cells
cultured with RAPA, the expression levels of anti-apoptotic Bcl-2
and Bcl-xL increased significantly (p,0.001), resulting in the Bcl-
2/Bax and Bcl-xL/Bax ratios of 1/2.6 and 1/1.2, respectively
(Figure 5). Similar data were obtained for the FLIP/Bax ratios
(data not shown). In aggregate, these results suggest that RAPA
up-regulated expression of the survival molecules in Treg, while in
CD4
+CD25
neg T cells it up-regulated expression of the pro-
apoptotic molecules. The data support the hypothesis that RAPA-
induced apoptosis may be the mechanism responsible for a demise
of CD4
+CD25
neg T cells and concomitantly for the selective
outgrowth of CD4
+CD25
+ Treg in the presence of this drug.
STAT3 and STAT5 signaling in CD4
+CD25
neg and
CD4
+CD25
high T cells6RAPA
To further evaluate the functional status of freshly-harvested or
RAPA expanded CD4
+CD25
neg or CD4
+CD25
high T cells, levels
of phosphorylated STAT5 and STAT3 were measured in these T
cells following short-term activation with cytokines. Single-cell
sorted CD4
+CD25
neg or CD4
+CD25
+ cells obtained from 6 NC
were incubated6RAPA, stimulated with the relevant cytokines
(150 IU/mL) for 20 min, permeabilized and treated with
phosphorylated (phospho) STAT5 or STAT3 Abs. At baseline
(no RAPA), phospho-STAT5 levels were higher in CD4
+CD25
high
T cells than in CD4
+CD25
neg T cells (Figure 6A). The levels of
phospho-STAT5 were up-regulated upon 4 h incubation+1n M
RAPA in CD4
+CD25
high T cells of all 6 NC but only moderately
in CD4
+CD25
neg cells of 2/6 NC. At the higher RAPA
concentration (50 nM) phospho-STAT5 levels tended to decline.
Table 1. Enrichment in CD4
+CD25
high Treg in cultures
containing various RAPA concentrations
a.
% CD4
+CD25
high T cells
range mean6SD
No RAPA 16–22 1968
+ RAPA 1 nM 71–79 7664
+ RAPA 10 nM 76–86 8166
+ RAPA 50 nM 85–95 8766
+ RAPA 100 nM 91–99 9669
aThe data are results of flow cytometry analyses using 3 week cultures of
CD4
+CD25
high T cells obtained from 6 subjects and expanded in the presence
or absence of RAPA. The gate was set on the CD4
+CD25
high subset of cultured
cells.
doi:10.1371/journal.pone.0005994.t001
RAPA Favors Expansion of Treg
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+CD25
high
cells of 2/6 donors and in CD4
+CD25
neg cells of 5/6 donors.
While incubation of CD4
+CD25
high cells with 1 nM RAPA
increased phospho-STAT3 expression in 5/6 donors, this up-
regulation was much less pronounced than that of STAT5
(compare Figures 6B and D). These data are consistent with the
hypothesis that activation of human Treg in the presence of RAPA
is mainly STAT5 dependent.
To compare RAPA effects on STAT signaling in CD4
+CD25
neg
and CD4
+CD25
high T cells cultured+1 nM RAPA, we measured
phospho-STAT5 and phospho-STAT3 levels following 20 min
stimulation of the cells with the relevant cytokines at baseline and
at different time points in culture. As expected, the levels of
phospho-STAT5 were considerably higher in CD4
+CD25
high than
in CD4
+CD25
neg T cells following stimulation with IL-2 alone
(Figures 7A and B). Upon RAPA addition and 1, 2 or 3 weeks in
culture, CD4
+CD25
high cells maintained high levels of STAT5
signaling. In contrast, in CD4
+CD25
neg T cells, initial IL-2
stimulation failed to up-regulate phospho-STAT5 and upon
RAPA addition, it remained at the baseline level. The high level
of STAT5 phosphorylation correlated with increased fold
expansion of the CD4
+CD25
high T cells and their high suppressor
function relative to those of CD4
+CD25
neg T cells (Table 4). The
addition of RAPA had a more dramatic effect on STAT3 signaling
in CD4
+CD25
high cells, as levels of phospho-STAT3 increased
throughout the culture period (Figure 7D). No such increase was
seen in CD4
+CD25
neg cells +RAPA (Figure 7C). These signalling
data are correlated to proliferation and suppression activity of the
relevant cell subsets in Table 4.
Overall, the above data indicate that RAPA-driven proliferation
of CD4
+CD25
high Treg is dependent on the STAT pathway. In
contrast, CD4
+CD25
neg T cells did not signal via STATs whether
in the presence or absence of RAPA.
Elevated PTEN expression in RAPA-expanded
CD4
+CD25
high cells
PTEN is a known negative regulator of the PI3K/mTOR
pathway [30]. It has been reported that in mice, high PTEN levels
are responsible for resistance of Treg to RAPA-induced apoptosis
[31]. Therefore, we studied PTEN expression levels in human
SCS CD4
+CD25
high and conventional CD4
+CD25
neg T cells6-
RAPA, with the expectation that the former will express high
levels of PTEN. About half of freshly isolated CD4
+CD25
high and
CD4
+CD25
neg T cells expressed PTEN. In cultures +RAPA, the
percent of PTEN
+CD4
+CD25
high T cells gradually increased to
reach close to 100% in 3 week cultures (Figure 8A). The MFI was
also significantly higher in fresh CD4
+CD25
high T cells, and in
culture, the high level of PTEN expression (MFI) remained
significantly higher than that in cultured CD4
+CD25
neg cells
(Figure 8C). In CD4
+CD25
neg T-cell cultures +RAPA, PTEN
+
cells declined in the frequency overtime (Figure 8A). The
proliferation and suppression data for the CD4
+CD25
high and
CD4
+CD25
neg T cell subsets used in these experiments are shown
in Figure 8B. These data are consistent with the hypothesis that a
high level of PTEN expression in Treg is important for their
resistance to RAPA-induced cell death.
PI3K/Akt/mTOR signalling in Treg
High levels of PTEN seen in Treg suggest that this survival
pathway may be blocked in these T cells. To further examine this
possibility, we studied phospho-Akt mTOR, phosphorylated
mTOR expression and downstream phosphorylation of 4E-PB1
and p70S 6K1 in CD4
+CD25
high and CD4
+CD25
neg T cells.
Western blot analyses showed that mTOR protein levels were
comparable in the freshly-isolated T-cell subsets and remained
unchanged in the presence of RAPA (data not shown).
Phosphorylation of Akt, upstream of mTOR, was negligible in
fresh CD4
+CD25
high T cells relative to that in CD4
+CD25
neg T
cells (Figure 8D). When phosphorylation of the downstream
targets, 4E-BP1 and p70S6K1, was examined in Western blots,
low or no expression of the phosphorylated proteins was evident in
fresh CD4
+CD25
high T cells. In contrast, their expression was high
in fresh CD4
+CD25
neg T cells as was that of phospho-Akt. By flow
cytometry (Figure 8E), the baseline expression of phosphorylated
4E-BP1 and p70S6K1 proteins was higher in the CD4
+CD25
neg T
cells than the CD4
+CD25
high cells, and after OKT3 and IL-2
stimulation, it was substantially upregulated only in the
CD4
+CD25
neg cells. In RAPA-containing cultures of these cells,
the expression of phosphorylated proteins in both the T cell
subsets was blocked (Figure 7D). The data are consistent with the
model suggesting that Treg do not utilize the PI3K/mTOR
pathway, because it is down-regulated by PTEN, while prolifer-
ation and survival of CD4
+CD25
neg conventional T cells depend
on this pathway and are inhibited by RAPA.
Discussion
For many years, RAPA (sirolimus) has been used as an
immunosuppressive drug that induces peripheral tolerance,
although the mechanism of its action is still not completely
understood. Specifically, little is known about the effects of RAPA
on expansion, function and survival of Treg subsets in man,
although in vitro and in vivo studies of murine Treg have provided
insights into molecular pathways that regulate Treg expansion
[reviewed in 32]. We and others have reported that RAPA has
potentiating effects on CD4
+CD25
+ Treg [16,22,23,25]. The
notion that RAPA may induce tolerance via expansion of Treg
numbers and enhancement of their function has introduced a
novel paradigm into RAPA activity as an immunosuppressive
drug.
In the present work, we demonstrate that in human PBMC
obtained from normal donors, RAPA selectively promotes
activation and expansion of highly suppressive CD4
+CD25
high-
Foxp3
+ Treg cells. These cells are resistant to apoptosis, while
activated conventional CD4
+CD25
neg T cells become highly
sensitive to RAPA, which has been reported to block the survival
PI3K/Akt/mTOR pathway these cells preferentially utilize [31].
Thus, responses to activation-induced cell death of human Treg
and Tconv appear to be divergently regulated in the presence of
RAPA. The CD4
+CD25
high Treg up-regulate expression of the
anti-apoptotic Bcl-2 family members (i.e., Bcl-2 and Bcl-xL) in the
presence of RAPA, while the conventional CD4
+CD25
neg T cells
significantly down-regulate expression of Bcl-2 or Bcl-xL increas-
ing the relative levels of pro-apoptotic Bax and thus promoting
Figure 3. Phenotypic analysis of CD4
+CD25
+ T cells cultured61 nM RAPA. A. MACS-purified CD4
+CD25
+ cells were cultured for 3 weeks, and
then their phenotype was assessed by flow cytometry. Culture conditions61 nM RAPA were as described in Materials and Methods. Freshly-isolated
CD4
+CD25
high T cells were similarly phenotyped. The flow cytometry data, obtained by gating on CD4
+CD25
high T cells in fresh PBMC or+RAPA
cultures, are mean percentages6SD from experiments with cells of 6 NC. The asterisks indicate significant differences at p,0.001 in the percentage
of positive cells relative to freshly isolated Treg.
doi:10.1371/journal.pone.0005994.g003
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+CD25
neg or CD8
+CD25
neg responder cells with T cells cultured61 nM RAPA. A. Fresh
MACS-purified CD4
+CD25
neg or CD8
+CD25
neg T cells were used as CFSE-labeled responders. Autologous MACS-isolated CD4
+CD25
+ T cells cultured in
presence of anti-CD3/CD28 beads and 1,000 IU/mL IL-2 in the presence or absence of 1 nM RAPA for 3 weeks were added at the 1:1 ratio to
responder cells. Gates were set on CD4
+ and CFSE
+ cells and analyzed using the ModFit program as described in Materials and Methods. Suppression
of responder cell proliferation is indicated as %. A representative experiment of 10 performed is shown. B. The mean percentages6SD of proliferation
suppression in CD4
+CD25
neg or CD8
+CD25
neg responder cells by suppressor cells generated in 3 week cultures61 nM RAPA (n=10). The p value is for
differences between suppression mediated by S from R0 vs. S from R1 cultures. C. Suppression levels mediated by Treg expanded with different
concentrations of RAPA. A representative experiment of 6 performed with cells of different NC is shown.
doi:10.1371/journal.pone.0005994.g004
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Bax or Bcl-xL/Bax ratio favoring anti-apoptotic proteins in the
CD4
+CD25
high T cells cultured with RAPA could be responsible
for resistance of Treg to apoptosis. Thus, our results provide a
rationale for the use of RAPA in order to expand human Treg that
are resistant to apoptosis and have potent suppressor functions.
Earlier data in mice have also suggested that RAPA might be used
in vivo to expand Treg subsets, while depleting the excess of
conventional T cells [31]. The definition of optimal conditions for
RAPA-driven Treg proliferation is an important objective,
because Treg are a minor component of peripheral blood
lymphocytes. The ability to reproducibly generate cultures of
pure, well-defined and highly suppressive Treg for adoptive
transfers to patients with autoimmune diseases or after transplan-
tation in the future remains a challenge. While Treg expansion
from cord blood has been previously described [18,20,21] and is
currently used for therapy to prevent post-transplant graft versus
host disease (GVHD), transfers of autologous, adult blood-derived
Treg are preferable in today’s regulatory climate and also more
feasible.
Expression of CD25 (IL-2Ra) on human nTreg suggest that
these cells are dependent on IL-2 for proliferation and survival.
Signaling via CD25 is crucial for the Treg development and
function [31], and no Treg are present in mice that are IL-2
deficient [33,34], IL-2Ra-deficient [34] or IL-2Rb-deficient [35].
Further, IL-2 directly regulates Foxp3 expression and proliferation
of human Treg via the STAT pathway [36]. Similarly, cytokine
production and proliferation of murine Treg has been shown to be
mainly STAT5-dependent [37]. In T cells, signaling downstream
of the IL-2R can proceed via the PI3K/Akt/mTOR or JAK/
STAT pathways. While RAPA inhibits the mTOR/PI3K
pathway in Treg, JAK/STAT signaling is not affected, sparing
Treg from RAPA-induced apoptosis [38]. The significant role of
Akt-mTOR pathway in regulating de novo differentiation of
CD4
+FOXP3
+ Treg has been emphasized by Haxhinasto et al
[39]. Battaglia and colleagues have speculated that RAPA may
have an inhibitory effect on IL-2 production by activated Tconv,
and that Treg able to effectively compete for IL-2 are favored to
expand in the presence of RAPA [40–42]. While murine
experiments indicate that IL-2 is required for expansion of Treg,
we have shown that IL-2 up-regulates expression of Bcl-2 and
Foxp3 in human Treg and that Treg suppressor functions depend
on the IL-2 concentration in their microenvironment [43]. Our
data demonstrating that RAPA enriches for CD4
+CD25
high T
cells with a high expression level of Foxp3 are consistent with this
paradigm. Expansion of IL-2 and TCR-activated Treg is regulated
by STAT5. The Foxp3 promoter has been shown to contain
consensus sequences which bind STAT5, resulting in high levels of
STAT5 expression in Treg [36]. Interestingly, STAT3 signaling
also appears to be up-regulated in CD3
+CD25
high cells by RAPA.
In aggregate, these in vitro results with human Treg support a large
body of murine data which indicate that in Treg, the STAT
signalling pathway is preferentially utilized over the PI3K
pathway.
PTEN is an oncogene involved in regulation of a broad
variety of cellular functions, including cell proliferation and cell
death [31]. PTEN is a negative regulator of the mTOR
pathway, and it inhibits IL-2R-mediated expansion of
CD4
+CD25
+ Treg [44]. Elevated PTEN levels observed in
human Treg suggest that these cells have a reduced usage of the
PI3K/mTOR pathway, in contrast to CD4
+CD25
neg Tconv,
which depend on the PI3K pathway for their proliferation and
survival. If PTEN blocks downstream events in the PI3K
pathway in CD4
+CD25
high T cells, then the reduced expression
of phosphorylated mTOR and phosphorylated 4E-BP1 and
p70S6K1 proteins should be evident in these cells relative to
CD4
+CD25
neg Tconv. Indeed, our results confirm this hypoth-
esis and suggest that Treg depended on the IL-2R-mediated
JAK/STAT signaling for proliferation, so that it is not inhibited
by RAPA. In contrast, CD4
+CD25
neg Tconv responding to
TCR and IL-2 stimulation signals via the PI3K pathway are
sensitive to RAPA-induced inhibition of proliferation. Recent
data of Buckler at al in mice suggest that by negatively
regulating TCR-mediated signals, PTEN imposes a requirement
for CD28 co-stimulation to assure T-cell proliferation and
survival [45]. Their observation together with our finding that
PTEN is highly expressed in human CD4
+CD25
high Treg might
explain why human postthymic Treg expanded in vitro in the
presence of RAPA require CD28 co-stimulation for survival and
suppressor function in vivo [46]. In this context, the CD28-PTEN
pathway might represent a novel regulation mechanism of
peripheral tolerance mediated by Treg.
Table 2. Suppressor activity of Treg in R0 and R cultures
a.
Suppressor cells Responder cells % suppression of proliferation p value
b
R0 CD4
+CD25
neg 1062.5
CD8
+CD25
neg 1869
R CD4
+CD25
neg 8066p ,0.0001
CD8
+CD25
neg 9665p ,0.001
aThe data are means6SD of percent suppression measured in co-cultures of proliferating autologous responder cells with Treg generated in R0 or R cultures. R cultures
were set up with 1 nM RAPA. Responder cells were either CD4
+CD25
neg or CD8
+CD25
neg. The co-cultures were established with cells obtained from 10 NC. The
responder cell to Treg ratios were 1:1 in all cultures.
bThe p values are for the differences in the % suppression between Treg in the R0 and R cultures.
doi:10.1371/journal.pone.0005994.t002
Table 3. Suppression of CD4
+CD25
2 cell proliferation by
CD4
+CD25
high T cells expanded in the presence of RAPA
a.
% suppression (mean6SD)
No RAPA 1063
RAPA 1 nM 7766
RAPA 50 nM 8465
RAPA 100 nM 9666
aSuppression of autologous responder cell proliferation with cells of 6 normal
donors. Treg and responder cells were obtained from PBMC and
cultured6RAPA as described in Materials and Methods.
doi:10.1371/journal.pone.0005994.t003
RAPA Favors Expansion of Treg
PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5994The observations we report for human Treg endorse the
molecular models of Treg signaling proposed for murine T
cells [25,30]. As Treg play a critical role in control of
autoimmune diseases, transplant rejection and cancer, a better
understanding of molecular signaling they utilize is essential
for improving therapeutic interventions in these diseases. While
the precise molecular mechanisms operating the survival or
death pathways in T cells are still under investigations, the
possibility of their pharmacologic manipulation in the future
might open the way for the development of new immuno-
therapeutic strategies that will permit the ‘‘long-term’’
induction and selective expansion of Treg or provide clues
about their selective elimination. The permanent depletion of
Treg in patients with cancer or infectious diseases might be
beneficial, allowing for expansion of T effector and helper T
cells and circumventing the side effects of current therapies
Figure 5. Expression levels the anti-apoptotic (Bcl-2 and Bcl-xL) and the pro-apoptotic (Bax) proteins in CD4
+CD25
+ or
CD4
+CD25
neg T cells measured before and after culture in the presence or absence of RAPA. The data are mean fluorescence intensity
(MFI) mean values (6SD) for Bcl-2, Bcl-xL and Bax expression levels obtained from measurements with freshly isolated T-cell subsets or T-cell subsets
cultured with RAPA or without RAPA. The ratios of Bcl-2/Bax or Bcl-xL/Bax are above the histograms. T cell subsets were separated by MACS from
PBMC of 10 NC and cultured as described in Materials and Methods.
doi:10.1371/journal.pone.0005994.g005
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activated T cells.
Materials and Methods
Media and reagents
All cell culture reagents, including AIM V, DMEM, RPMI
1640 media, phosphate-buffered saline (PBS), streptomycin (S),
penicillin (P), sodium pyruvate L-glutamine, non-essential amino
acids, and trypan blue dye were purchased from Gibco/
Invitrogen, Grand Island, NY. Culture media, were supplemented
with pre-tested human AB serum (8%, v/v) purchased from
Geminie Bioproducts (West Sacramento, CA), penicillin (100 IU/
mL), streptomycin (100 mg/mL) and L-glutamine (2 mM/L) and
cell cultures were incubated at 37uC in an atmosphere of 5% CO2
in air. Recombinant human IL-2 (rh IL-2) was purchased from
Peprotech, Rocky Hill, NJ. Anti-CD3 mAb (OKT3) was obtained
from ATCC, Rockville, MD. Anti-CD3 and anti-CD28 mAb-
coated beads were from Beckman Coulter, Miami, FL. Rapamy-
cin (RAPA), saponin and Brefeldin A were from Sigma, St. Louis,
MO. Recombinant human (rh) IL-6 was purchased from
Cellgenix, Antioch, IL.
Antibodies for flow cytometry
The following anti-human mAbs were used for flow cytometry
analysis: anti-CD3-ECD, anti-CD4-PC5, anti-CD25-FITC and -
PE, anti-CD122-FITC, anti-CD132-PE, anti-CD45RO-FITC,
anti-Fas-FITC, anti-IFNc-FITC, anti-CD62L-FITC and anti-
CD152-PE were purchased from Beckman Coulter, (Miami,
FL); anti-h/TNFRSF18-GITR (clone FAB689F) and anti-CCR7-
FITC from R&D Systems, Inc., (Minneapolis, MN); anti-TGF-b1
(unconjugated) was from Antigenix America, Inc., (Huntington
Station, NY); anti-Foxp3-FITC (clone PCH101); anti-IL-4-FITC
and anti-CD127-FITC from eBioscience (San Diego, CA); anti-
FasL-PE (NOK-1.42 kDa) and anti-Perforin-FITC from Biole-
gend (San Diego, CA); anti-Granzyme B-PE (clone GB111) from
PeliCluster Inc, (Netherlands) and anti-Granzyme A-PE, anti-
CD45RA-FITC, anti-IL-10-PE and isotype controls IgG1, IgG2a
Figure 6. Activation of STAT5/3 proteins in CD4
+CD25
neg and CD4
+CD25
high T cells cultured at different RAPA concentrations. Mean
fluorescence intensity (MFI) of phosphorylated STAT5 in CD4
+CD25
neg and CD4
+CD25
high T cells in A, and of phosphorylated STAT3 in B. T cells were
tested by flow cytometry immediately after isolation and after short-term (4 h) culture with different RAPA concentrations (1 nM or 50 nM). Before
analysis, the cells were briefly stimulated with 150 IU/mL IL-2 (A and B) or with 150 IU/mL IL-6 (C and D) and stained for phosphorylated STAT5 or
phosphorylated STAT3, respectively. The gate was set on CD3
+CD4
+CD25
neg or CD3
+CD4
+CD25
high cells, respectively. Results obtained with T cells of
6 different NC are shown.
doi:10.1371/journal.pone.0005994.g006
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CA). The following antibodies were used to study the anti- or pro-
apoptotic pathways involved in responses to rapamycin: anti-Bcl2-
FITC, anti-Bcl-xL-FITC, anti-Bax-FITC (Santa Cruz Biotechnol-
ogy Inc., CA), anti-Bid (unconjugated; Abcam, Cambridge, MA)
and anti-FLIP (unconjugated; Genway Biotech, Inc., San Diego,
CA. Additional Abs used for flow cytometry were all purchased
from Cell Signaling, Danvers, MA and included: anti-PTEN-
Alexa Fluor 488, anti-phospho-4E-BP1-Alexa Fluor 488 and anti-
phospho-p70S6 Kinase polyclonal, unconjugated used with FITC-
donkey anti-rabbit IgG (Jackson Immuno Research Laboratories)
as a secondary Ab. Prior to use, all mAbs were titrated using
normal resting or activated PBMC to establish optimal staining
dilutions.
Cell isolation and separation
Peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coats obtained from 21 normal donors (Central Blood Bank
of Pittsburgh) on Ficoll-Hypaque density gradients (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ). Cells recovered from the
gradient interface were washed twice in RPMI 1640 medium,
counted and separated into monocytes and lymphocytes via plastic
Figure 7. Activation of STAT5/3 proteins in fresh (untreated) and RAPA-expanded CD4
+CD25
neg and CD4
+CD25
high T cells. Mean
fluorescence intensity (MFI) of phosphorylated STAT5 in CD4
+CD25
neg in A, and CD4
+CD25
high T cells in B and of phosphorylated STAT3 in
CD4
+CD25
neg in C and CD4
+CD25
high T cells in D. PBMC-derived T cells were sorted into CD4
+CD25
neg and CD4
+CD25
+ populations and tested by
flow cytometry immediately after isolation and after culture in the presence of 1 nM RAPA (at baseline unstimulated, in medium) or were briefly
stimulated with 150 IU/mL IL-2 (A and B) or with 150 IU/mL IL-6 (C and D) just before analysis. In addition, T cells were cultured for the indicated
periods of time and stimulated with IL-2 and IL-6 just before flow cytometry analysis. The gate was set on CD3
+CD4
+CD25
neg or CD3
+CD4
+CD25
high T
cells, respectively. RAPA was added to T-cell cultures at the indicated concentrations. Data obtained with T cells of 6 NC are shown. Fold expansion
and percent suppression mediated by these cells are shown in Table 4.
doi:10.1371/journal.pone.0005994.g007
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magnetic cell isolation using AutoMACS (Miltenyi Biotec,
Auburn, CA) as previously described [16]. CD4
+ T cells were
negatively selected with a CD4
+ T-cell isolation kit (Miltenyi
Biotec, Auburn, CA), yielding populations of CD4
+ cells with
the 96–99% purity. Next, CD4
+CD25
+ T cells were separated
from CD4
+CD25
neg T cells on the AutoMACS in two repetitive
separation steps using CD4
+CD25
+ T Regulatory Cell Isolation
Kit (Milltenyi Biotec). Positively selected CD4
+CD25
+ T cells
and negatively depleted CD4
+CD25
neg T cell fractions (purity
.98%) were immediately used for expansion protocols or
suppression assays. Aliquots of the CD4
+CD25
neg cells were
cryopreserved to be used as autologous responder cells in
suppression assays.
Expansion of human CD4
+CD25
+ Treg
Using a previously developed protocol [16], we cultured
MACS-isolated T cells in the presence of anti-CD3/CD28 Ab-
coated beads and IL-2 [16,27]. Briefly, purified CD4
+CD25
+
or CD4
+CD25
neg T cells (1610
5 cells/well) were initially
cultured in 96-well plates in AIM V medium supplemented
with soluble OKT3 (1 mg/mL), IL-2 (150 IU/mL) and
irradiated (3,000R) autologous feeder cells (2 feeder cells to 1
Treg) for 5 to 7 d. Next, the cells were transferred to wells of
a 24-well plates (at least 2.5 to 3610
5 cells/well) and re-
stimulated with anti-CD3/CD28 mAb-coated beads (1 viable
cell to 4 beads). On the 3rd day, IL-2 (1,000 IU/mL) was
added and the cells were cultured for 7–8 days. On Day 8,
the cells were re-stimulated with anti-CD3/CD28 mAb and
IL-2 (1,000 IU/mL) and RAPA at the final concentration of 1,
10, 50 or 100 nM was added to half of the cultures. Cultures
were supplemented with fresh medium plus RAPA as needed.
After 3 weeks of expansion in the presence of RAPA the beads
were removed using a magnet and the cells counted. Cells (at
least 6610
5 cells/well) were transferred to wells of 6-well plates
and again re-stimulated with anti-CD3/CD28 mAb-coated
beads and 1,000 IU/mL IL-2 in the presence or absence of
RAPA for 1-2 weeks. On the final day of culture anti-CD3/
CD28 mAb-coated beads were removed, cells were washed in
medium, counted in the presence of a trypan blue dye and
resuspended in medium containing 50 IU/mL of IL-2 for 24–
48 h prior to all phenotypic or functional assays. Expanding T
cells were routinely analyzed at 3 different time points: at
weeks 1, 3 and 6. R0 are cultures of CD4
+CD25
+ or
CD4
+CD25
neg T cells in the absence of RAPA, while+R are
cultures of these T cell subsets+RAPA.
Surface and intracellular staining
After harvest, cells were washed and stained with the above
listed Abs for 15 min at 4uC as previously described [16,28].
Appropriate isotype control Abs were used for each sample.
Following staining, cells were examined by four-color flow
cytometry.
Intracellular staining was performed as previously described
[16]. Expression levels of TGF-b1, IL-10, Foxp3, CTLA-4, BcL-2,
Bax, BcL-xL, PTEN, 4E-PB1 and p70S6K1 were assessed before
and after activation of cells with anti-CD3/CD28 beads and IL-2
(6RAPA). Briefly, samples were first incubated with mAbs against
surface markers. After washing, cells were fixed with 4% (v/v)
paraformaldehyde in PBS for 20 min at RT, washed once with
flow solution (PBS containing 0.5% (v/v) BSA and 2 nM EDTA),
permeabilized with PBS containing 0.5% BSA (v/v) and 0.1% (v/
v) saponin and stained with detection Abs specific for intracyto-
plasmic proteins for 30 min at RT. Cells were further washed
twice with PBS containing 0.5% BSA (v/v) and 0.2% (v/v)
saponin, fixed with 4% (w/v) paraformaldehyde and analyzed by
flow cytometry. Appropriate isotype controls were included for
each sample. Cells stained with the primary unconjugated Ab were
incubated with the secondary Ab (anti-rabbit-FITC-IgG,
1500 ng/mL) purchased from Jackson ImmunoResearch Labora-
tories Inc., West Grove, PA, or with a control secondary Ab (anti-
mouse-FITC-IgG at 1:10 dilution; Beckman Coulter) in saponin
for 15 min, washed twice with PBS containing 0.5% BSA and
0.2% (v/v) saponin and analyzed by flow cytometry.
Suppression assays
Responder CD4
+CD25
2 T cells (RC) were autologous to
suppressor cells (S). Freshly-isolated RC were cryopreserved. Prior
to their use in suppression assays, RC were thawed and
maintained in medium plus 50 IU/mL of IL-2 for 48 h. RC
were stained with 1.5 mM CFSE (Molecular Probes/Invitrogen,
Carlsbad, CA) as previously described [16] and co-cultured with S
in a complete AIM V medium containing IL-2 (150 IU/mL),
plate-bound OKT3 (1 mg/mL) and soluble anti-CD28 Ab (1 mg/
mL) in wells of 96-well plates (at least 5610
5/well). S were
CD4
+CD25
high or CD4
+CD25
neg T cells expanded6RAPA under
conditions described above for 3–6 weeks and added to RC at the
S:R ratios of 1:1, 1:5 and 1:10. Co-cultures were incubated at
37uC in an atmosphere of 5% CO2 in air for 3–5 d. After harvest,
suppression of CFSE-labeled RC proliferation was analyzed. Data
obtained by flow cytometry were analyzed as previously described
by us [3,5,16] using ModFit LT for Win32 software provided by
Verity Software House, Inc., Topsham, ME. The percentages of
suppression were calculated based on the proliferation index (PI) of
RC alone compared with the PI of cultures containing RC and
Treg. The program determines the percent of cells within each
peak, and the sum of all peaks in the control culture is taken as
100% of proliferation and 0% of suppression.
Annexin V binding
The binding of ANX V-FITC (Apoptosis Detection Kits, BD
PharMingen) to phos-phatidylserine on T-cell surface was used as
a measure of apoptosis. Stained samples were analyzed by flow
cytometry. The gates were set to include the live (PI-) as well as the
dead (PI+) cells present in each sample.
Expression of phosphorylated STAT3/5 proteins
Expression of phosphorylated STAT3 and STAT5 in
CD4
+CD25
high Treg and conventional (CD4
+CD25
neg) T cells
was determined in freshly purified T cell subsets following a brief
Table 4. Treg cultured in the presence of RAPA up-regulated
phospho-STAT5 as well as phospho-STAT3, had higher
expansion rates and mediated higher suppression of
autologous T responder cells than Tconv
a.
CD4
+CD25
high CD4
+CD25
neg
no RAPA + RAPA no RAPA + RAPA
Fold proliferation 6623 9 69* 75611* 63
% suppression 11627 8 67* 0 762
aThe proliferation fold and percent suppression (at the 1:1 ratio of Treg to RC)
observed in 3 week cultures of Treg obtained from the 6 NC, whose Treg and
Tconv were tested for phospho-STAT3 and phospho-STAT5 as shown in
Figure 7. The data are mean percentages6SD. Asterisks indicate significant
differences between no RAPA and+RAPA cultures at p,0.001.
doi:10.1371/journal.pone.0005994.t004
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+CD25
high and CD4
+CD25
neg T cells. A. Percentages of
PTEN
+ cells tested fresh (no RAPA) or after culture +RAPA for the indicated time periods. B. The MFI for PTEN expression in fresh and RAPA-expanded
T cell cultures. C. Fold expansion and % suppression mediated by the same CD4
+CD25
high and CD4
+CD25
high T cell subsets cultured6RAPA on week
3. The data in A–C are means6SD from 6 experiments with cells of normal donors. Asterisks indicate significant differences between CD4
+CD25
high
and CD4
+CD25
neg cells at p,0.001. C. Results of Western blots comparing expression levels of phospho-Akt, phospho-4EBP-1 and phospho-p70S6 in
CD4
+CD25
high and CD4
+CD25
neg T cell subsets6RAPA. T cells were either unstimulated or stimulated with bead-coated anti-CD3/CD28 Abs and
100 IU/mL of IL-2 for 2 h and cultured in the presence of RAPA for the indicated time periods. The cells were harvested and used for Western blots. D.
Flow cytometry histograms showing expression of phospho-4EBP-1 and phospho-p70S6 in freshly-isolated CD4
+CD25
high and CD4
+CD25
neg T cells
subsets. Cells were stimulated as described above for 24 h and cultured in the presence of RAPA. They were harvested, permeabilized, stained and
examined by flow ctyometry. Results are from one out of 3 experiments performed.
doi:10.1371/journal.pone.0005994.g008
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150 IU/mL IL-6 (STAT3-expression). Cells were culture-
d6RAPA for a short (4 hr) or longer time periods (1, 2, 3 or 4
weeks), harvested, washed, stimulated with the cytokines for
20 min and then stained for analysis with anti-CD3-ECD, anti-
CD4-PC5 and anti-CD25-PE Abs followed by intracellular
staining with the anti-phosphorylated STAT5 Ab (pY694) labeled
with Alexa Fluor-488 or the Ab specific for phosphorylated
STAT3 Ab (pY705)-Alexa Fluor-488 (both from BD Biosciences).
The gate for flow cytometry was set on CD3
+CD4
+ cells and then
on CD25
neg or CD25
high cells.
Western blot analysis
Cells (CD4
+CD25
+ and CD4
+CD25
neg) were lysed at 4uC at the
concentration of 0.5610
6 cells/mL. The lysis buffer, SDS-PAGE
electrophoresis and blotting conditions were as previously
described [29]. Membranes were washed and probed with the
following polyclonal Abs, all purchased from Cell Signaling:
phospho-p70S6Kinase (Thr 389); phospho-4E-BP1 (Thr 37/47);
mTOR (7Clo) rabbit mAb; phospho-mTOR (Ser 2448); phospho-
mTOR (Ser 2481); phospho-PI3Kp85 (Tyr 458)/p55. Blots were
visualized by ECL (Roche Diagnostics, Indianapolis, IN) accord-
ing to the manufacturer’s protocol. For reprobing, Abs were first
stripped using Restore Western Blot stripping buffer (Pierce,
Rockford, IL) and then the membranes were blotted with the
second Ab.
Statistical Analysis
The arithmetic means and SD values were calculated for all
parameters in at least ten independent experiments. Statistical
analysis of differences in all of the data was done using the one-way
ANOVA test. P values ,0.05 were considered significant.
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Found at: doi:10.1371/journal.pone.0005994.s001 (1.91 MB TIF)
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